Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IMNN)

Celsion Corporation Reports Second Quarter 2015 Financial Results and Provides Business Update

PR Newswire August 10, 2015

Celsion Corporation Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer

PR Newswire August 6, 2015

Celsion Corporation Announces Updated Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer

PR Newswire August 6, 2015

Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015

PR Newswire August 3, 2015

Celsion Announces Continuing Positive Data from Its Phase 2 DIGNITY Study in Breast Cancer

PR Newswire July 6, 2015

Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015

PR Newswire July 1, 2015

Celsion Presents GEN-1 Immunotherapy Phase 1b Results in Recurrent Ovarian Cancer at ASCO 2015

PR Newswire June 1, 2015

Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering

PR Newswire May 28, 2015

Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence(TM) RNA Program

PR Newswire May 21, 2015

Celsion Announces Publication of Preclinical Data Demonstrating Lung Specific Delivery of microRNA-145 Inhibitor Using Its Novel TheraSilence(TM) Platform

PR Newswire May 15, 2015

Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation

PR Newswire May 13, 2015

Celsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update

PR Newswire May 12, 2015

Celsion Corporation to Hold First Quarter 2015 Financial Results Conference Call on Tuesday, May 12, 2015

PR Newswire May 5, 2015

Celsion Expands Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer

PR Newswire April 29, 2015

Celsion Corporation Announces Appointment of Harriet Shelare to Director, Communications

PR Newswire April 27, 2015

Celsion Announces Positive Interim Data from its Phase 2 DIGNITY Study in Breast Cancer

PR Newswire April 15, 2015

Celsion Corporation Reports Year End 2014 Financial Results and Provides Business Update

PR Newswire March 12, 2015

Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015

PR Newswire March 5, 2015

Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer

PR Newswire February 23, 2015

Celsion Corporation Presents Clinical and Preclinical Data for GEN-1 IL-12 Immunotherapy in Ovarian Cancer at the Molecular Medicine TRI-Conference

PR Newswire February 20, 2015